CHEYENNE, Wyo., Feb. 1, 2017 /PRNewswire/ -- The directors and management of N1 Technologies Corp. (OTC PINK: NNSV) announced today that the company's Bio Tech division has signed an agreement with Phage Consultants Co. of Dansk Poland and its director Dr. Marcin Los. Phage Consultants is a leader in bacteriophage research and development and Dr. Los is highly recognized as a visionary in the area of Phage research. The agreement establishes a timeline for the development of a genetically enhanced Bacteriophage that will be highly effective in treating Staphylococcus infections. Staph infection affects millions of patients around the world each year. Many strains have become difficult to treat and resistant to available antibiotics. Viritron VDX which is in the early stages of development is a genetically modified organism that targets Staph bacteria and destroys it. Targeted Phage treatments have been proven effective in various studies conducted around the world. "We are excited to be working with Phage Consultants and Dr. Los, and look forward to working with him on this project," says CEO Steve Lovern. The agreement calls for a 22 month R&D timeline, which includes the manufacturing and distribution of the Viritron VDX treatment. N1 Technologies will market the treatments to countries where current regulations permit it. The company will seek U.S. and European approvals in the future after accumulating data from its use in various markets.
In Other News, NanoSave Technolgies has posted its Q4 2016 Financial statements which reflect the company's recent acquisition of the Viritron VDX, Viritron VPN and Viritron Mini Lab Patents. The company continues to expand rapidly, corporate accountants have indicated that the forth quarter numbers were clearly positive and may have exceeded initial expectations. "We feel very strongly that our numbers will be a pleasant surprise as we combine the operating accounts of NanoSave and N1 into a consolidated financial statement, with both assets and revenues hitting all time highs. We are looking forward to opening new markets in the bio technology arenas and streamlining all aspects of our operations," says Company CEO Steve Lovern. The company envisages these new Bio Tech Patents and Technologies as an exceptional opportunity for our investors going forward. NanoSave Technologies designs, develops, manufactures and markets a wide range of nano-engineered products. Q4Financials:
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "will" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanosave-technologies-enters-major-bio-research-deal-300399817.html
SOURCE NanoSave Technologies Inc. NNSV